US2909462A
(en)
|
1955-12-08 |
1959-10-20 |
Bristol Myers Co |
Acrylic acid polymer laxative compositions
|
US4168062A
(en)
|
1977-12-05 |
1979-09-18 |
Mccarthy Gerald F |
Automated goalie
|
US4258029A
(en)
|
1979-04-23 |
1981-03-24 |
Connaught Laboratories Limited |
Synthetic adjuvants for stimulation of antigenic responses
|
US4769330A
(en)
|
1981-12-24 |
1988-09-06 |
Health Research, Incorporated |
Modified vaccinia virus and methods for making and using the same
|
US5505941A
(en)
|
1981-12-24 |
1996-04-09 |
Health Research, Inc. |
Recombinant avipox virus and method to induce an immune response
|
US5364773A
(en)
|
1991-03-07 |
1994-11-15 |
Virogenetics Corporation |
Genetically engineered vaccine strain
|
US5174993A
(en)
|
1981-12-24 |
1992-12-29 |
Health Research Inc. |
Recombinant avipox virus and immunological use thereof
|
US5110587A
(en)
|
1981-12-24 |
1992-05-05 |
Health Research, Incorporated |
Immunogenic composition comprising synthetically modified vaccinia virus
|
US4603112A
(en)
|
1981-12-24 |
1986-07-29 |
Health Research, Incorporated |
Modified vaccinia virus
|
US4722848A
(en)
|
1982-12-08 |
1988-02-02 |
Health Research, Incorporated |
Method for immunizing animals with synthetically modified vaccinia virus
|
US5378457A
(en)
|
1981-12-24 |
1995-01-03 |
Virogenetics Corporation |
Interferon sensitive recombinant poxvirus vaccine
|
US5833975A
(en)
|
1989-03-08 |
1998-11-10 |
Virogenetics Corporation |
Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
|
US4436727A
(en)
|
1982-05-26 |
1984-03-13 |
Ribi Immunochem Research, Inc. |
Refined detoxified endotoxin product
|
US4882278A
(en)
|
1983-04-29 |
1989-11-21 |
President And Fellows Of Harvard College |
Non-toxinogenic vibrio cholerae mutants
|
US4945050A
(en)
|
1984-11-13 |
1990-07-31 |
Cornell Research Foundation, Inc. |
Method for transporting substances into living cells and tissues and apparatus therefor
|
ZA8681B
(en)
|
1985-01-07 |
1987-08-26 |
Syntex Inc |
1,2-dialkoxy-omega-trialkylammonium cationic surfactants
|
DE3521994A1
(de)
|
1985-06-20 |
1987-01-02 |
Bayer Ag |
N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
|
US5078996A
(en)
|
1985-08-16 |
1992-01-07 |
Immunex Corporation |
Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
|
US5141742A
(en)
|
1986-02-07 |
1992-08-25 |
Oncogen |
Vaccines against melanoma
|
US5122599A
(en)
|
1986-08-13 |
1992-06-16 |
Molecular Diagnostics, Inc. |
CDNAS coding for members of the carcinoembryonic antigen family
|
US5015580A
(en)
|
1987-07-29 |
1991-05-14 |
Agracetus |
Particle-mediated transformation of soybean plants and lines
|
US5504005A
(en)
|
1987-03-02 |
1996-04-02 |
Albert Einstein College Of Medicine Of Yeshiva University |
Recombinant mycobacterial vaccine
|
JP3011939B2
(ja)
|
1987-03-02 |
2000-02-21 |
ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ |
組換えミコバクテリア・ワクチン
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
CA1331443C
(en)
|
1987-05-29 |
1994-08-16 |
Charlotte A. Kensil |
Saponin adjuvant
|
US6699475B1
(en)
|
1987-09-02 |
2004-03-02 |
Therion Biologics Corporation |
Recombinant pox virus for immunization against tumor-associated antigens
|
CA1341245C
(en)
|
1988-01-12 |
2001-06-05 |
F. Hoffmann-La Roche Ag |
Recombinant vaccinia virus mva
|
EP0326423B1
(en)
|
1988-01-29 |
1995-05-24 |
Eli Lilly And Company |
Vectors, compounds and methods for expression of a hum adenocarcinoma antigen
|
JPH01193227A
(ja)
|
1988-01-29 |
1989-08-03 |
Res Dev Corp Of Japan |
癌免疫療法補助剤
|
US5804381A
(en)
|
1996-10-03 |
1998-09-08 |
Cornell Research Foundation |
Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
|
US5093258A
(en)
|
1988-08-26 |
1992-03-03 |
Therion Biologics Corporation |
Recombinant fowlpox virus and recombination vector
|
US6780407B1
(en)
|
1989-03-08 |
2004-08-24 |
Aventis Pasteur |
Pox virus comprising DNA sequences encoding CEA and B7 antigen
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
DE69032284T2
(de)
|
1989-03-21 |
1998-10-08 |
Vical Inc |
Expression von exogenen polynukleotidsequenzen in wirbeltieren
|
US5076908A
(en)
|
1989-07-19 |
1991-12-31 |
Chevron Research & Technology Company |
Method and apparatus for an on-stream particle replacement system for countercurrent contact of a gas and liquid feed stream with a packed bed
|
CA2076753A1
(en)
|
1990-02-26 |
1991-08-27 |
Anthony J. Radford |
Shuttle plasmid for escherichia coli and mycobacteria
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
GB9015888D0
(en)
|
1990-07-19 |
1990-09-05 |
Smithkline Biolog |
Vectors
|
EP0468520A3
(en)
|
1990-07-27 |
1992-07-01 |
Mitsui Toatsu Chemicals, Inc. |
Immunostimulatory remedies containing palindromic dna sequences
|
SE9003978D0
(sv)
|
1990-12-13 |
1990-12-13 |
Henrik Garoff |
Dna expressionssystem baserade paa ett virus replikon
|
WO1992011354A1
(en)
|
1990-12-18 |
1992-07-09 |
The General Hospital Corporation |
VIBRIO CHOLERAE STRAINS DEFECTIVE IN irgA EXPRESSION, AND CHOLERA VACCINES DERIVED THEREFROM
|
WO1992011361A1
(en)
|
1990-12-18 |
1992-07-09 |
The General Hospital Corporation |
Improved vaccines
|
US5843456A
(en)
*
|
1991-03-07 |
1998-12-01 |
Virogenetics Corporation |
Alvac poxvirus-rabies compositions and combination compositions and uses
|
KR100242671B1
(ko)
|
1991-03-07 |
2000-03-02 |
고돈 에릭 |
유전학적으로 처리한 백신 균주
|
JP3399943B2
(ja)
|
1991-05-06 |
2003-04-28 |
アメリカ合衆国 |
癌胎児性抗原を発現する組換えウイルスとその使用方法
|
US6235525B1
(en)
|
1991-05-23 |
2001-05-22 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
|
US5342774A
(en)
|
1991-05-23 |
1994-08-30 |
Ludwig Institute For Cancer Research |
Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
|
WO1992021376A1
(en)
|
1991-06-06 |
1992-12-10 |
Med Immune, Inc. |
Induction of ctl responses to foreign antigens expressed in mycobacteria
|
US5283185A
(en)
|
1991-08-28 |
1994-02-01 |
University Of Tennessee Research Corporation |
Method for delivering nucleic acids into cells
|
US5637483A
(en)
|
1991-10-04 |
1997-06-10 |
Whitehead Institute For Biomedical Research |
Irradiated tumor cell vaccine engineered to express GM-CSF
|
US5904920A
(en)
|
1991-10-04 |
1999-05-18 |
Whitehead Institute For Biomedical Research |
Regulation of systemic immune responses utilizing cytokines and antigens
|
DE69333814T2
(de)
|
1992-03-11 |
2006-02-02 |
Powderject Vaccines, Inc., Madison |
Genetischer impfstoff gegen den immunschwäche virus
|
CA2131620A1
(en)
|
1992-03-20 |
1993-09-30 |
Louis C. Smith |
A dna transporter system and method of use
|
DE69333434T2
(de)
|
1992-04-03 |
2005-03-03 |
The Regents Of The University Of California, Oakland |
Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
|
EP0761231B1
(en)
|
1992-06-25 |
2000-01-12 |
SMITHKLINE BEECHAM BIOLOGICALS s.a. |
Vaccine composition containing adjuvants
|
CN1083524A
(zh)
|
1992-07-06 |
1994-03-09 |
哈佛大学校长及研究员协会 |
作为霍乱疫苗缺失突变体
|
MX9304089A
(es)
|
1992-07-08 |
1994-01-31 |
Schering Corp |
Uso de gm-csf como una vacuna adyuvante.
|
US5405940A
(en)
|
1992-08-31 |
1995-04-11 |
Ludwig Institute For Cancer Research |
Isolated nonapeptides derived from MAGE genes and uses thereof
|
US6222012B1
(en)
|
1992-08-31 |
2001-04-24 |
Ludwig Institute For Cancer Research |
Isolated nonapeptides presented by HLA molecules, and uses thereof
|
US5462871A
(en)
|
1992-08-31 |
1995-10-31 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules which encode MAGE derived nonapeptides
|
US5744316A
(en)
|
1992-12-22 |
1998-04-28 |
Ludwig Institute For Cancer Research |
Isolated, tyrosinase derived peptides and uses thereof
|
US5519117A
(en)
|
1992-12-22 |
1996-05-21 |
Ludwig Institute For Cancer Research |
Isolated, tyrosinase derived peptides and uses thereof
|
AU675702B2
(en)
|
1993-01-26 |
1997-02-13 |
Leslie R. Coney |
Compositions and methods for delivery of genetic material
|
DE69434951D1
(de)
|
1993-02-22 |
2007-05-24 |
Gen Hospital Corp |
Heterologe antigene in stämmen zur impfung mit lebendzellen
|
US5869445A
(en)
|
1993-03-17 |
1999-02-09 |
University Of Washington |
Methods for eliciting or enhancing reactivity to HER-2/neu protein
|
IL108915A0
(en)
|
1993-03-18 |
1994-06-24 |
Merck & Co Inc |
Polynucleotide vaccine against influenza virus
|
AU685443B2
(en)
|
1993-03-23 |
1998-01-22 |
Smithkline Beecham Biologicals (Sa) |
Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
|
TW404844B
(en)
|
1993-04-08 |
2000-09-11 |
Oxford Biosciences Ltd |
Needleless syringe
|
SG54115A1
(en)
|
1993-04-27 |
1998-11-16 |
Gerber Scient Products Inc |
Thermal printing apparatus with improved power supply
|
US5919676A
(en)
|
1993-06-24 |
1999-07-06 |
Advec, Inc. |
Adenoviral vector system comprising Cre-loxP recombination
|
US5562909A
(en)
|
1993-07-12 |
1996-10-08 |
Massachusetts Institute Of Technology |
Phosphazene polyelectrolytes as immunoadjuvants
|
ES2211882T3
(es)
|
1993-07-14 |
2004-07-16 |
The Regents Of The University Of California |
Sistema de cesion de polinucleotido, automontable que comprende policationes de dendrimeros.
|
CA2168582A1
(en)
|
1993-08-06 |
1995-02-16 |
John D. Fikes |
Cloning and characterization of the complete mage-1 gene
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
TW442569B
(en)
|
1993-10-25 |
2001-06-23 |
Canji Inc |
Recombinant adenoviral vector
|
GB9326174D0
(en)
|
1993-12-22 |
1994-02-23 |
Biocine Sclavo |
Mucosal adjuvant
|
GB9326253D0
(en)
|
1993-12-23 |
1994-02-23 |
Smithkline Beecham Biolog |
Vaccines
|
US5554724A
(en)
|
1994-03-24 |
1996-09-10 |
University Of Leiden |
Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
|
US5554506A
(en)
|
1994-03-24 |
1996-09-10 |
Ludwig Institute For Cancer Research |
Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
|
US5651981A
(en)
|
1994-03-29 |
1997-07-29 |
Northwestern University |
Cationic phospholipids for transfection
|
SE9401091D0
(sv)
|
1994-03-31 |
1994-03-31 |
Bioption Ab |
Alphavirus cDNA vectors
|
CA2188432C
(en)
*
|
1994-04-22 |
2011-02-01 |
Yutaka Kawakami |
Melanoma antigens
|
US5874560A
(en)
|
1994-04-22 |
1999-02-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Melanoma antigens and their use in diagnostic and therapeutic methods
|
US5759535A
(en)
|
1994-05-13 |
1998-06-02 |
Research Corporation Technologies, Inc. |
Immunotherapeutic strategies for the treatment of cancer
|
SE9401709D0
(sv)
|
1994-05-18 |
1994-05-18 |
Mathilda Sjoeberg |
Improved alphavirus vectors for expression of heterologous DNA
|
US6060257A
(en)
|
1994-06-03 |
2000-05-09 |
Ludwig Institute For Cancer Research |
Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
|
US20030072774A1
(en)
|
1994-06-10 |
2003-04-17 |
Diane M. Gajewczyk |
Proteinaceous adjuvants
|
ES2267100T5
(es)
|
1994-07-15 |
2011-04-08 |
The University Of Iowa Research Foundation |
Oligonucleótidos inmunomoduladores.
|
US6019982A
(en)
|
1994-08-26 |
2000-02-01 |
The Administrators Of The Tulane Educational Fund |
Mutant enterotoxin effective as a non-toxic oral adjuvant
|
US5527928A
(en)
|
1994-09-30 |
1996-06-18 |
Nantz; Michael H. |
Cationic transport reagents
|
AU688606B2
(en)
|
1994-10-03 |
1998-03-12 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
|
US6045802A
(en)
|
1994-10-03 |
2000-04-04 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
|
AU712714B2
(en)
|
1994-10-03 |
1999-11-11 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system
|
AUPM873294A0
(en)
|
1994-10-12 |
1994-11-03 |
Csl Limited |
Saponin preparations and use thereof in iscoms
|
FR2726764B1
(fr)
|
1994-11-14 |
1997-01-31 |
Pasteur Merieux Serums Vacc |
Adjuvant pour composition vaccinale
|
US5843648A
(en)
|
1995-01-10 |
1998-12-01 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
|
US6001349A
(en)
|
1995-02-22 |
1999-12-14 |
Therion Biologics Corporation |
Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
|
WO1996030534A1
(en)
|
1995-03-24 |
1996-10-03 |
Genzyme Corporation |
Adenovirus vectors for gene therapy
|
GB9620795D0
(en)
|
1996-10-05 |
1996-11-20 |
Smithkline Beecham Plc |
Vaccines
|
UA56132C2
(uk)
|
1995-04-25 |
2003-05-15 |
Смітклайн Бічем Байолоджікалс С.А. |
Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
|
US5792462A
(en)
|
1995-05-23 |
1998-08-11 |
University Of North Carolina At Chapel Hill |
Alphavirus RNA replicon systems
|
US5807978A
(en)
|
1995-06-07 |
1998-09-15 |
Kokolus; William J. |
Immunogenic peptides of prostate specific antigen
|
US6127116A
(en)
*
|
1995-08-29 |
2000-10-03 |
Washington University |
Functional DNA clone for hepatitis C virus (HCV) and uses thereof
|
US6951917B1
(en)
|
1995-09-26 |
2005-10-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
MHC-class II restricted melanoma antigens and their use in therapeutic methods
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
WO1997015597A1
(en)
|
1995-10-25 |
1997-05-01 |
Centocor B.V. |
HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
|
JP2001520511A
(ja)
|
1995-12-08 |
2001-10-30 |
ザ ユーナヴァーサティ オブ アラバマ アト バーミングハム リサーチ ファンデーション |
向標的性アデノウイルス・ベクター
|
JP4359654B2
(ja)
*
|
1996-01-30 |
2009-11-04 |
ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア |
抗原特異的免疫応答を生起させる遺伝子発現ベクターおよびその使用方法
|
US6096313A
(en)
|
1996-02-09 |
2000-08-01 |
Ludwig Institute For Cancer Research |
Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
|
US5840839A
(en)
|
1996-02-09 |
1998-11-24 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
|
US6083703A
(en)
|
1996-02-09 |
2000-07-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
|
FR2746110B1
(fr)
|
1996-03-14 |
1998-04-17 |
|
Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
|
WO1997034613A1
(en)
|
1996-03-19 |
1997-09-25 |
University Of Virginia Patent Foundation |
Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor
|
WO1997039771A1
(en)
|
1996-04-22 |
1997-10-30 |
The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services |
Heterologous boosting immunizations
|
FR2748753B1
(fr)
|
1996-05-20 |
1998-08-14 |
Transgene Sa |
Nouveaux vecteurs adenoviraux pour la therapie genique
|
US6805869B2
(en)
|
1996-06-12 |
2004-10-19 |
Shanghai Cp Guojian Pharmaceutical Co., Ltd. |
Cellular vaccines and immunotherapeutics and methods for their preparation
|
WO1997047271A2
(en)
*
|
1996-06-12 |
1997-12-18 |
Yajun Guo |
Cellular vaccines and immunotherapeutics and methods for their preparation
|
US20050136066A1
(en)
|
1996-06-12 |
2005-06-23 |
Yajun Guo |
Cellular vaccines and immunotherapeutics and methods for their preparation
|
ZA975858B
(en)
*
|
1996-07-11 |
1998-09-01 |
Akzo Nobel Nv |
Melanoma associated peptide analogues and vaccines against melanoma
|
US20040156861A1
(en)
|
1996-07-11 |
2004-08-12 |
Figdor Carl Gustav |
Melanoma associated peptide analogues and vaccines against melanoma
|
SE510778C2
(sv)
|
1996-07-11 |
1999-06-21 |
Sandvik Ab |
Belagt skär för finfräsning av grått gjutjärn
|
WO1998004728A1
(en)
*
|
1996-07-25 |
1998-02-05 |
Therion Biologics Corporation |
Recombinant pox virus for immunization against tumor-associated antigens
|
US6265215B1
(en)
|
1996-09-13 |
2001-07-24 |
Ludwig Institute For Cancer Research |
Isolated peptides which complex with HLA-Cw16 and uses thereof
|
AU729690B2
(en)
|
1996-10-10 |
2001-02-08 |
Henrik Garoff |
Alphavirus-retrovirus vectors
|
US6610661B1
(en)
|
1996-10-11 |
2003-08-26 |
The Regents Of The University Of California |
Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
|
ES2153654T3
(es)
|
1996-10-17 |
2001-03-01 |
Oxford Biomedica Ltd |
Vectores retrovirales.
|
GB9621680D0
(en)
|
1996-10-17 |
1996-12-11 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
ATE429929T1
(de)
*
|
1996-10-23 |
2009-05-15 |
Univ Pennsylvania |
Verbesserte impfstoffe
|
US5994132A
(en)
|
1996-10-23 |
1999-11-30 |
University Of Michigan |
Adenovirus vectors
|
US7255862B1
(en)
*
|
1996-11-14 |
2007-08-14 |
Connaught Technology Corporation |
ALVAC/FIV constructs
|
WO1998033810A2
(en)
|
1997-01-30 |
1998-08-06 |
University Of Virginia Patent Foundation |
Cysteine-depleted peptides recognized by a3-restricted cytotoxic lymphocytes, and uses therefor
|
JP2001513643A
(ja)
|
1997-03-06 |
2001-09-04 |
ウーベルラ、クラウス |
レンチウイルスをベースとするベクター及びベクター系
|
US5990091A
(en)
|
1997-03-12 |
1999-11-23 |
Virogenetics Corporation |
Vectors having enhanced expression, and methods of making and uses thereof
|
US20010007659A1
(en)
|
1997-04-17 |
2001-07-12 |
The University Of California |
Use of lentiviral vectors for antigen presentation in dendritic cells
|
AU741747B2
(en)
|
1997-05-13 |
2001-12-06 |
University Of North Carolina At Chapel Hill, The |
Lentivirus-based gene transfer vectors
|
GB9711957D0
(en)
|
1997-06-09 |
1997-08-06 |
Isis Innovation |
Methods and reagents for vaccination
|
GB9711990D0
(en)
|
1997-06-11 |
1997-08-06 |
Smithkline Beecham Biolog |
Vaccine
|
WO1998058956A2
(en)
|
1997-06-23 |
1998-12-30 |
Ludwig Institute For Cancer Research |
Methods for inducing an immune response involving prime-boost protocols
|
EP1012173B1
(en)
|
1997-06-23 |
2007-10-31 |
Ludwig Institute For Cancer Research |
Isolated decapeptides which bind to hla molecules, and the use thereof
|
US6656734B1
(en)
*
|
1997-07-01 |
2003-12-02 |
Transgene S.A. |
Compositions for the delivery of polynucleotides to cells
|
ATE325619T1
(de)
*
|
1997-07-10 |
2006-06-15 |
Mannkind Corp |
Vorrichtung zur induktion einer ctl-antwort
|
US6977074B2
(en)
|
1997-07-10 |
2005-12-20 |
Mannkind Corporation |
Method of inducing a CTL response
|
US6994851B1
(en)
|
1997-07-10 |
2006-02-07 |
Mannkind Corporation |
Method of inducing a CTL response
|
AU4110097A
(en)
|
1997-08-29 |
1999-03-22 |
Sue-May Kang |
Method and apparatus for voluntary motor controlled convalescence
|
ES2500490T3
(es)
|
1997-08-29 |
2014-09-30 |
Antigenics Inc. |
Composiciones que comprenden el adyuvante QS-21 y polisorbato o ciclodextrina como excipiente
|
GB9718901D0
(en)
|
1997-09-05 |
1997-11-12 |
Smithkline Beecham Biolog |
Vaccine
|
WO2000000600A2
(en)
|
1997-09-22 |
2000-01-06 |
Chang Lung Ji |
Lentiviral vectors, comprising modified major donor splice sites and major packaging signals
|
AU747438B2
(en)
|
1997-09-24 |
2002-05-16 |
Regents Of The University Of California, The |
Non-primate lentiviral vectors and packaging systems
|
DE69837273T2
(de)
|
1997-10-08 |
2008-01-31 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen
|
US6756038B1
(en)
|
1997-10-10 |
2004-06-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
AU745863B2
(en)
|
1997-10-10 |
2002-04-11 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
|
AU1087299A
(en)
|
1997-10-14 |
1999-05-03 |
Avant Immunotherapeutics, Inc. |
Non-integrating dna vector of retroviral origin having high-protein expres sion, and secreted immunogenic antigens
|
WO1999027101A1
(en)
|
1997-11-25 |
1999-06-03 |
Princeton University |
Method for preparing adenovirus vectors, vectors so prepared, and uses thereof
|
AU749059B2
(en)
|
1997-12-12 |
2002-06-20 |
Cell Genesys, Inc. |
Therapeutic use of lentiviral vectors
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
GB9726555D0
(en)
*
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Vaccine
|
US6709844B1
(en)
|
2000-11-16 |
2004-03-23 |
Mannkind Corporation |
Avoidance of undesirable replication intermediates in plasmid propagation
|
EP1071325A4
(en)
*
|
1998-03-20 |
2004-12-22 |
Genzyme Corp |
COMPOSITIONS AND METHODS FOR SPECIFIC VACCINATION OF THE ANTIGEN
|
AU758265B2
(en)
*
|
1998-03-20 |
2003-03-20 |
Genzyme Corporation |
Induction of immunity against tumor self-antigens
|
BR9909173A
(pt)
|
1998-03-27 |
2000-12-05 |
Secr Defence |
ácido nucleico, mutante de deleção de um alfa-vìrus, adenovìrus recombinante, vìrus vacìnia recombinante, plasmìdeo, vacina, e, processo para produzir uma imune resposta protetora a um alfa-vìrus
|
US6171855B1
(en)
|
1998-05-28 |
2001-01-09 |
The Regents Of The University Of Michigan |
Vectors
|
CA2330211A1
(en)
|
1998-06-08 |
1999-12-16 |
Karel Petrak |
Formulations for electroporation
|
US6693086B1
(en)
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
US20030022854A1
(en)
*
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
US6407063B1
(en)
|
1998-10-02 |
2002-06-18 |
Ludwig Institute For Cancer Research |
Tumor antigens and CTL clones isolated by a novel procedure
|
EP1117679B9
(en)
|
1998-10-02 |
2010-07-07 |
Ludwig Institute For Cancer Research |
Tumor antigens and ctl clones isolated by a novel procedure
|
PT1137792E
(pt)
*
|
1998-12-09 |
2007-08-10 |
Therion Biolog Corp |
Vector recombinado que exprime moléculas costimulantes múltiplas e as suas utilizações
|
ATE492644T1
(de)
*
|
1999-09-09 |
2011-01-15 |
Curevac Gmbh |
Transfer von mrna unter verwendung von polykationischen verbindungen
|
EP1808180A3
(en)
*
|
1999-10-22 |
2010-12-22 |
Sanofi Pasteur Limited |
Modified GP 100 and uses thereof
|
US6861234B1
(en)
|
2000-04-28 |
2005-03-01 |
Mannkind Corporation |
Method of epitope discovery
|
DE60238864D1
(de)
|
2001-11-07 |
2011-02-17 |
Mankind Corp |
Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
|
NL1023791C2
(nl)
|
2003-07-01 |
2005-01-04 |
Lely Entpr Ag |
Melkinstallatie.
|